Skip to main content

The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis

Abstract

BACKGROUND: Exogenous melatonin has been increasingly used in the management of sleep disorders.

PURPOSE: To conduct a systematic review of the efficacy and safety of exogenous melatonin in the management of primary sleep disorders.

DATA SOURCES: A number of electronic databases were searched. We reviewed the bibliographies of included studies and relevant reviews and conducted hand-searching.

STUDY SELECTION: Randomized controlled trials (RCTs) were eligible for the efficacy review, and controlled trials were eligible for the safety review.

DATA EXTRACTION: One reviewer extracted data, while the other verified data extracted. The Random Effects Model was used to analyze data.

DATA SYNTHESIS: Melatonin decreased sleep onset latency (weighted mean difference [WMD]: −11.7 minutes; 95% confidence interval [CI]: −18.2, −5.2)); it was decreased to a greater extent in people with delayed sleep phase syndrome (WMD: −38.8 minutes; 95% CI: −50.3, −27.3; n=2) compared with people with insomnia (WMD: −7.2 minutes; 95% CI: −12.0, −2.4; n=12). The former result appears to be clinically important. There was no evidence of adverse effects of melatonin.

CONCLUSIONS: There is evidence to suggest that melatonin is not effective in treating most primary sleep disorders with short-term use (4 weeks or less); however, additional large-scale RCTs are needed before firm conclusions can be drawn. There is some evidence to suggest that melatonin is effective in treating delayed sleep phase syndrome with short-term use. There is evidence to suggest that melatonin is safe with short-term use (3 months or less).

This is a preview of subscription content, access via your institution.

References

  1. 1.

    National Institutes of Health. National Center on Sleep Disorder Research Plan. 2003.

  2. 2.

    Roller L. Treating sleep disorders. Aust J Pharm. 2002;83:443–7.

    Google Scholar 

  3. 3.

    American Psychiatric Association. American Psychiatric Task Force on DSM-IV, Diagnostic and Statistical Manual of Mental Disorders: DSM IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.

    Google Scholar 

  4. 4.

    Grustein R. Insomnia diagnosis and management. Aust Fam Phys. 2002;31:995–1000.

    Google Scholar 

  5. 5.

    American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Revised. Diagnostic and Coding Manual. Rochester, Minn: American Academy of Sleep Medicine; 2001.

    Google Scholar 

  6. 6.

    Regestein QR, Pavlova M. Treatment of delayed sleep phase syndrome. Gen Hosp Psychiatr. 1995;17:335–45.

    Article  CAS  Google Scholar 

  7. 7.

    Wyatt JK. Delayed sleep phase syndrome: pathophysiology and treatment options. Sleep. 2004;27:1195–203.

    PubMed  Google Scholar 

  8. 8.

    Reite M, Ruddy J, Nagel K. Evaluation and Management of Sleep Disorders. 3rd ed. Washington, DC: American Psychiatric Publishing Inc; 2002.

    Google Scholar 

  9. 9.

    Wagner DR. Circadian rhythm sleep disorders. Curr Treat Options Neurol. 1999;1:299–308.

    PubMed  Article  Google Scholar 

  10. 10.

    Czeisler CA, Kronauer RE, Allan JS, et al. Bright light induction of strong (type 0) resetting of the human circadian pacemaker. Science. 1989;244:1328–33.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab. 2003;17:273–85.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Anton-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci-Part 1-Physiol Pharmacol. 1971;10:841–50.

    Article  CAS  Google Scholar 

  13. 13.

    Cramer H, Rudolph J, Consbruch U, Kendel K. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol. 1974;11:187–91.

    PubMed  CAS  Google Scholar 

  14. 14.

    Arendt J, Borbely AA, Franey C, Wright J. The effects of chronic, small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study. Neurosci Lett. 1984;45:317–21.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ. Effects of melatonin on human mood and performance. Brain Res. 1984;323:201–7.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996;17:1–12.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc. 1995;273:408–12.

    Article  CAS  Google Scholar 

  18. 18.

    Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. J Epidemiol Commun Health. 1998;52:377–84.

    CAS  Article  Google Scholar 

  19. 19.

    DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177–88.

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Deeks JJ, Higgins JPT, Altman DG. Cochrane Statistical Methods Group. Analysing and presenting results: Section 8. In: Alderson P, Green S, Higgins JPT, eds. Cochrane Reviewer’s Handbook 4.2.2 [updated March 2004]; The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons Ltd.; 2004.

    Google Scholar 

  21. 21.

    Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

    PubMed  Article  Google Scholar 

  22. 22.

    Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Eggar M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in context. 3rd ed. London: BMJ Publishing Group; 2001:285–312.

    Google Scholar 

  23. 23.

    Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995;346:541–4.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr. 1997;24:223–31.

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Smits MG, van Stel HF, van der Heijden K, Meijer AM, Coenen AM, Kerkhof GA. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatr. 2003;42:1286–93.

    Article  Google Scholar 

  26. 26.

    Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86:4727–30.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Andrade C, Srihari BS, Reddy KP, Chandramma L. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatr. 2001;62:41–5.

    CAS  Article  Google Scholar 

  28. 28.

    Dawson D, Rogers NL, van den Heuvel CJ, Kennaway DJ, Lushington K. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J Biol Rhythm. 1998;13:532–8.

    Article  CAS  Google Scholar 

  29. 29.

    Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res. 1996;5:61–5.

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Baskett JJ, Broad JB, Wood PC, et al. Does melatonin improve sleep in older people?: a randomized crossover trial. Age Ageing. 2003;32:164–70.

    PubMed  Article  Google Scholar 

  31. 31.

    Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. Child Neurol. 2001;16:86–92.

    CAS  Google Scholar 

  32. 32.

    Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med. 2001;63:40–8.

    PubMed  CAS  Google Scholar 

  33. 33.

    Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to melatonin. Lancet. 1991;337:1121–4.

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Montes LG, Ontiveros Uribe MP, Cortes Sotres J, Heinze Martin G. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatr Neurosci. 2003;28:191–6.

    Google Scholar 

  35. 35.

    Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ). 2004;108:1–7.

    Google Scholar 

  36. 36.

    Moher D, Sampson M, Campbell K, et al. Assessing the quality of reports of randomized trials in paediatric complementary and alternative medicine. BMC Paediatr. 2002;2:2 (available at: http://www.biomedcentral.com/1471-2431/2/2).

    Article  Google Scholar 

  37. 37.

    Nahin RL, Straus SE. Research into complementary and alternative medicine problems and potential. BMJ. 2001;322:161–4.

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996;124:485–9.

    PubMed  CAS  Google Scholar 

  39. 39.

    Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167–70.

    PubMed  Article  Google Scholar 

  40. 40.

    Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase response curve. Chronobiol Int. 1992;9:380–92.

    PubMed  CAS  Google Scholar 

  41. 41.

    Ioannidis JPA, Evans SJW, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–8.

    PubMed  Google Scholar 

  42. 42.

    Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–43.

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Loke YK, Derry S. Reporting of adverse drug reactions in randomized controlled trials—a systematic survey. BMC. Clin Pharmacol. 2001;1:3.

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Barnes J, Mills S, Abbot N, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medications: face-to-face interviews with 515 users of herbal remedies. Br Clin Pharmacol. 1998;45:496–500.

    Article  CAS  Google Scholar 

  45. 45.

    Moher D, Pham B, Lawson M, Klassen TP. The inclusion of reports of randomized trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7:1–90.

    PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Nina Buscemi PhD.

Additional information

Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality, the National Center for Complementary and Alternative Medicine or the U.S. Department of Health and Human Services.

None of the authors have any conflicts of interest to declare.

This article is based on research conducted by the University of Alberta Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (Contract No. 290-02-0023), Rockville, Md and support from the National Center for Complementary and Alternative Medicine, National Institute for Health, Bethesda, Md.

Financial support: This study was conducted under contract to the Agency for Healthcare Research and Quality (Contract No. 290-02-0023), Rockville, Md and support from the National Center for Complementary and Alternative Medicine, National Institute for Health, Bethesda, Md.

Authors’ contributions: N.B. planned, oversaw and participated in all steps of the systematic review process and in writing and editing the manuscript.

B.V. performed all statistical analyses and participated in writing and editing the manuscript.

N.H. participated in most steps of the systematic review process and in writing and editing the manuscript.

R.P. participated in all steps of the systematic review process and reviewed the manuscript.

L.T. conducted the literature search, provided technological expertise for the inclusion process, and participated in editing the manuscript.

L.H. participated in writing the proposal, provided methodological expertise, and participated in writing and editing the manuscript.

G.B. participated in writing the proposal, provided content expertise and participated in editing the manuscript.

T.K. participated in writing the proposal, provided methodological expertise and provided feedback on the manuscript.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Buscemi, N., Vandermeer, B., Hooton, N. et al. The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis. J GEN INTERN MED 20, 1151–1158 (2005). https://doi.org/10.1111/j.1525-1497.2005.0243.x

Download citation

Key Words

  • melatonin
  • sleep
  • primary
  • review